Navigation Links
ULURU Inc. Reports Third Quarter 2011 Financial Results
Date:11/15/2011

g to our patents of $88,000, commission expense of $30,000 and legal fees of $30,000.  These expense decreases were partially offset by an increase in shareholder expenses of $56,000 relating to investor relations consulting.

Mr. Gray continued, "Significant progress was reported in the third quarter, including financing, a strategic partnership, and clinical data. We achieved an important milestone in the third quarter with the signing of a binding letter of intent for the marketing of Altrazeal® in Europe. Positive clinical data has been produced in Europe in a number of hospitals and key opinion leaders' support is being generated. Plans for producing the initial launch quantities are being developed. This agreement has significant economic benefits to the Company both in the short and longer term. Additionally, further clinical data supporting the use of Altrazeal® in accelerating healing of diabetic foot ulcers was presented at a wound care conference; this is important data as it was in combination with a removable off-loading device which is the major segment of this market. We have also continued our efforts and made advancements towards completing additional partnerships to execute our business plan."

About ULURU Inc.:ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com.  For further information about Altrazeal®, please visit our website at www.altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a o
'/>"/>

SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
2. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
4. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
5. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
6. ULURU Inc. Reports Second Quarter 2010 Financial Results
7. ULURU Inc. Announces Conference Call
8. ULURU Inc. Provides Altrazeal® Clinical Update
9. ULURU Inc. Reports Third Quarter 2010 Financial Results
10. ULURU Inc. to Raise $500,000 in Registered Direct Offering
11. ULURU Inc. Announces Agreement With Exciton to Develop Antimicrobial Dressing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Ill. , July 22, 2014  UL ... announced that the U.S. Food and Drug Administration ... as consensus standards for medical devices incorporating lithium ... 2054 - Standard for Household and Commercial Batteries, ... (Cells). Consensus standards are standards ...
(Date:7/22/2014)... N.J. , July 22, 2014  Vernalis plc ... achievement of proof-of-concept (POC) for CCP-08, the third ... prescription cough cold collaboration. Under this collaboration, POC ... a successful human pilot comparative study against an ... achieving POC, Vernalis will make a milestone payment ...
(Date:7/22/2014)... SAN MARCOS, Texas , July 22, 2014 Quantum ... Martin and Mr. John Heaton to the Board ... chaired by Dr. Ghassan Jabbour , QMC Chief Science Officer ... Dr. Michael Wong of Rice University and Mr. ... Japan . " Quantum Materials ...
Breaking Medicine Technology:Two UL Battery Safety Standards Are now FDA Recognized Consensus Standards for Medical Devices 2Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 2Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 3Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 2Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 3Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 4
... Bowl champion coach, Fox NFL Sunday host and ... ExtenZe, the male enhancement brand, he has good-naturedly taken a ... national television. Now, in this next flight of ... fun, laughing about being put on the spot and made ...
... AMGN ) today announced that results from ... be presented at the 35th European Society for Medical ... "Cancer is a complex disease which ... pathways to develop novel therapies to treat cancer and ...
Cached Medicine Technology:Two-Time Super Bowl Champion Coach & Sports Broadcaster Jimmy Johnson Laughs About His 'Notoriety' in New ExtenZe Spots from Inter/Media Advertising 2Two-Time Super Bowl Champion Coach & Sports Broadcaster Jimmy Johnson Laughs About His 'Notoriety' in New ExtenZe Spots from Inter/Media Advertising 3Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 2Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 3Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 4Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 5Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 6Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 7Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 8Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 9Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 10Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 11Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 12Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 13Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 14Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 15Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 16
(Date:7/22/2014)... SIMpalm, a leading Mobile App Development ... Payment System. Forte Mobile Payment app allows merchants to ... and iPad. The app was originally launched in ... This update was for iOS 7.0 compatibility and iPhone ... and is available to download on the iPhone app ...
(Date:7/22/2014)... cholesterol treatment and cardiovascular risk assessment state that men ... atherosclerotic cardiovascular disease or of having a heart attack ... profile (based on age, smoking history, and cholesterol and ... when and how aggressively to treat high cholesterol are ... Health , a peer-reviewed publication from Mary Ann Liebert, ...
(Date:7/22/2014)... TX (PRWEB) July 22, 2014 The ... Program and third annual Institute Scholar Program. These offerings ... of the patient experience in healthcare and the need ... , The grant and scholar programs are ... , Value of focusing on the patient ...
(Date:7/22/2014)... New York, NY (PRWEB) July 22, 2014 ... Risperdal lawsuits ( http://www.risperdallawsuitcenter.com/ ) in ... his decision to deny punitive damages in cases ... (male breast growth), Bernstein Liebhard LLP reports. In ... New also denied a plaintiffs’ request to certify ...
(Date:7/22/2014)... park is the heart of a community. That’s ... made a recent investment in outdoor recreation and fun ... equipment from American Parks Company™. , The community of ... a 475-unit community that was established in the 1970s. ... tropical paradise with lush shade trees, green-edged walking and ...
Breaking Medicine News(10 mins):Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 2Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 3Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 2Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 3
... with The Bakersfield based Comprehensive Blood and Cancer center (CBCC), ... an other six months the CBCC of US is to ... Kuruvilla the CEO of Apollo Hospital said that, "It will ... have within the hospital premises a separate unit that will ...
... A new ultra light hand, called the 'Southampton Remedi-Hand' has been ... hand better than any currently available. // ,The human hand ... movements and actions. The artificially developed hand is dependent on 6 ... way so as to enable independent movement of all the five ...
... that their neighborhoods are safe then their preschool children ... points out that this does not mean that these ... comparison with their counterparts in unsafe neighborhoods. ,Drawing ... researchers reported these findings in the September issue of ...
... acid as found to reduce the rate of birth defects. ... found that more than one third of birth defects are ... Spina bifida and anencephaly, known as neural-tube defects, arise when ... close during the first weeks of pregnancy. The defect causes ...
... emergency room with cervical spinal injury may have more damage ... published in the Annals of Emergency Medicine, say that CT ... over and above the normal X-rays.// ,The study indicates ... additional spinal damage not visible on regular x-rays. In fact, ...
... announcement the Health Minister of West Bengal Mr.Surya Kanta Mishra ... and the numbers of cases detected were increasing in ... other than dengue, malaria, typhoid, viral fever and encephalitis were ... was also reported in N.Delhi last week in India. Dengue ...
Cached Medicine News:Health News:New ultralight hand with better functionality and flexibility developed 2Health News:Safe Neighborhood Means Less TV For Preschool Children 2Health News:Folic acid enriched grain reduces birth defects 2
BD Vacutainer® Fluoride Tubes - Glass...
BD Vacutainer® Specialty Tubes - Trace Element - Glass...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....
Medicine Products: